EMYRIA LIMITED - Announcements

6.52%

4.9¢

Market Cap $29.96M

Healthcare Biotechnology

Emyria Limited is an Australia-based early-stage drug development company. The Company is... Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) to benefit as Denmark commits to cannabis pilot program.

Announcements

Filter Results

All Price Sensitive Only

EMD	Application for quotation of securities - EMD		21/11/23	29.03KB	Share
EMD	Results of Annual General Meeting		16/11/23	91.89KB	Share
EMD	Final Director's Interest Notice - A. Vickery		13/11/23	157.32KB	Share
EMD	Board Changes and Executive Restructuring	PRICE SENSITIVE	13/11/23	714.67KB	Share
EMD	Section 708A(5)(e) Notice		10/11/23	88.02KB	Share
EMD	Application for quotation of securities - EMD		10/11/23	26.82KB	Share
EMD	Notification regarding unquoted securities - EMD		10/11/23	30.81KB	Share
EMD	Change of Director's Interest Notice - A. Vickery		10/11/23	286.07KB	Share
EMD	Results of General Meeting		31/10/23	101.9KB	Share
EMD	Emyria Secures Ethics Endorsement for MDMA AP Application	PRICE SENSITIVE	30/10/23	453.79KB	Share
EMD	ASA Virtual Investor Summit Presentation October 2023		27/10/23	6.31MB	Share
EMD	September 2023 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	26/10/23	2.01MB	Share
EMD	Change in substantial holding		24/10/23	114.12KB	Share
EMD	Health Canada Approval Received for MDMA Import	PRICE SENSITIVE	19/10/23	708.64KB	Share
EMD	Letter to Shareholders - Notice of Annual General Meeting		13/10/23	266.63KB	Share
EMD	Notice of Annual General Meeting/Proxy Form		13/10/23	519.44KB	Share
EMD	Section 708A(5)(e) Notice		10/10/23	87.79KB	Share
EMD	Notification of cessation of securities - EMD		10/10/23	23.41KB	Share
EMD	Application for quotation of securities - EMD		10/10/23	26.79KB	Share
EMD	Change of Director's Interest Notice x 3		10/10/23	364.15KB	Share
EMD	Change in substantial holding		10/10/23	137.8KB	Share
EMD	Emyria's Clinic Achieves Key MDMA-AT Dosing Milestone	PRICE SENSITIVE	09/10/23	764.02KB	Share
EMD	Application for quotation of securities - EMD		05/10/23	26.74KB	Share
EMD	Notification regarding unquoted securities - EMD		05/10/23	25.98KB	Share
EMD	Completion of Entitlement Offer	PRICE SENSITIVE	05/10/23	784.09KB	Share
EMD	Letter to Shareholders - Notice of General Meeting		28/09/23	265.44KB	Share
EMD	Notice of General Meeting/Proxy Form		28/09/23	474.82KB	Share
EMD	2023 Annual Report		27/09/23	4.81MB	Share
EMD	Appendix 4G and Corporate Governance Statement		27/09/23	489.9KB	Share
EMD	Emyria Secures Local MDMA to Start PTSD Trial Dosing	PRICE SENSITIVE	21/09/23	770.68KB	Share
EMD	Prospectus & Application Forms Available to Eligible Holders		18/09/23	169.82KB	Share
EMD	Notice to Ineligible Shareholders of Entitlement Offer		13/09/23	252.68KB	Share
EMD	Section 708A(5)(e) Notice		13/09/23	88.76KB	Share
EMD	Emyria Completes Acquisition of the Pax Centre	PRICE SENSITIVE	13/09/23	763.21KB	Share
EMD	Application for quotation of securities - EMD		13/09/23	29.24KB	Share
EMD	Application for quotation of securities - EMD		13/09/23	26.79KB	Share
EMD	Notice to Optionholders - Non-Renounceable Entitlement Offer		06/09/23	231.06KB	Share
EMD	Becoming a substantial holder		06/09/23	212.88KB	Share
EMD	Strategic Update & Entitlement Offer Presentation	PRICE SENSITIVE	06/09/23	9.15MB	Share
EMD	Prospectus	PRICE SENSITIVE	06/09/23	635.86KB	Share
EMD	Notification of cessation of securities - EMD		05/09/23	22.87KB	Share
EMD	Proposed issue of securities - EMD		04/09/23	57.25KB	Share
EMD	Emyria Gets $2M Bids, Sets $3.1M Entitlement Offer	PRICE SENSITIVE	04/09/23	854.7KB	Share
EMD	Trading Halt	PRICE SENSITIVE	31/08/23	723.52KB	Share
EMD	Appendix 4E Preliminary Financial Report	PRICE SENSITIVE	30/08/23	253.14KB	Share
EMD	2023 Annual General Meeting - Key Dates		30/08/23	220.93KB	Share
EMD	Final Director's Interest Notice - M. Callahan		23/08/23	157.11KB	Share
EMD	Initial Director's Interest Notice - M. Kaushal		23/08/23	184.96KB	Share
EMD	Notification of cessation of securities - EMD		23/08/23	23.18KB	Share
EMD	Notification regarding unquoted securities - EMD		23/08/23	29.11KB	Share
EMD	Emyria Announces Strategic Board Transition		21/08/23	795.63KB	Share
EMD	Change of Director's Interest Notice - A. Vickery		11/08/23	228.3KB	Share
EMD	Change of Director's Interest Notice - S. Washer		10/08/23	232.72KB	Share
EMD	Change of Director's Interest Notice - M. Winlo		09/08/23	225.45KB	Share
EMD	Emyria Launches Ketamine-Assisted Therapy Program	PRICE SENSITIVE	08/08/23	1.22MB	Share
EMD	June 2023 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	31/07/23	773.99KB	Share
EMD	Emyria Recruits First Patient MDMA-Assisted Therapy Trial	PRICE SENSITIVE	10/07/23	925.91KB	Share
EMD	Presentation - Pax Acquisition and Company Update	PRICE SENSITIVE	06/07/23	7.92MB	Share
EMD	Proposed issue of securities - EMD		03/07/23	25.5KB	Share
EMD	Pax Centre Acquisition to Advance Psychedelic Therapies	PRICE SENSITIVE	03/07/23	1.1MB	Share
EMD	Trading Halt	PRICE SENSITIVE	29/06/23	374.84KB	Share
EMD	Emyria Receives Ethics Approval for MDMA-assisted Therapy	PRICE SENSITIVE	08/06/23	717.18KB	Share
EMD	Section 708A(5)(e) Notice		10/05/23	303.92KB	Share
EMD	Application for quotation of securities - EMD		10/05/23	26.56KB	Share
EMD	Notification regarding unquoted securities - EMD		10/05/23	30.02KB	Share
EMD	Proposed issue of securities - EMD		01/05/23	29.17KB	Share
EMD	Emyria Completes $2.5m Placement	PRICE SENSITIVE	01/05/23	630.65KB	Share
EMD	March 2023 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	28/04/23	815.17KB	Share
EMD	Trading Halt	PRICE SENSITIVE	27/04/23	700.42KB	Share
EMD	Emyria Unveils Highest Potency CBD Capsule for FDA Pathway	PRICE SENSITIVE	24/04/23	631.36KB	Share
EMD	Emyria to Develop Psilocybin Therapy Care Model	PRICE SENSITIVE	18/04/23	1.16MB	Share
EMD	Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5	PRICE SENSITIVE	04/04/23	1.16MB	Share
EMD	Strong Recruitment for EMD-RX5 Phase 3 Trial	PRICE SENSITIVE	23/03/23	1.19MB	Share
EMD	Emyria Grows MDMA Asset for Neuro & Mental Health Therapy	PRICE SENSITIVE	20/03/23	638.15KB	Share
EMD	Broker Briefing Presentation		16/03/23	6MB	Share
EMD	Broker Briefing Biotech & Nutrition Investor Webinar		15/03/23	527.52KB	Share
EMD	Emyria partners with PAX Centre for MDMA-assisted therapy	PRICE SENSITIVE	07/03/23	627.19KB	Share
EMD	Company Secretary Change		01/03/23	541.02KB	Share
EMD	Notice under section 708A(5)(e) of the Corporations Act		27/02/23	304.68KB	Share
EMD	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/23	1.65MB	Share
EMD	Investor Presentation		24/02/23	6.55MB	Share
EMD	Change of Director's Interest Notice x 5		23/02/23	395.42KB	Share
EMD	Notification regarding unquoted securities - EMD		23/02/23	25.44KB	Share
EMD	Application for quotation of securities - EMD		23/02/23	26.47KB	Share
EMD	Emyria secures clinical-grade MDMA supply for Aust patients	PRICE SENSITIVE	13/02/23	544.06KB	Share
EMD	Emyria expands MDMA programs following landmark TGA decision	PRICE SENSITIVE	06/02/23	1.81MB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	31/01/23	742.38KB	Share
EMD	Change in substantial holding SW		31/01/23	102.46KB	Share
EMD	First dosing commenced for pivotal EMD-RX5 Phase 3 trial	PRICE SENSITIVE	30/01/23	959.35KB	Share
EMD	Results of Meeting		25/01/23	532.4KB	Share
EMD	Emyria receives $2.1M R&D tax incentive refund	PRICE SENSITIVE	12/01/23	526.56KB	Share
EMD	Biotech Showcase San Francisco Presentation		10/01/23	10.45MB	Share
EMD	Notification of cessation of securities - EMD		05/01/23	22.67KB	Share
EMD	Letter to Shareholders/Notice of General Meeting/Proxy Form		16/12/22	1.03MB	Share
EMD	Notice under section 708A(5)(e) of the Corporations Act		07/12/22	278.45KB	Share
EMD	Application for quotation of securities - EMD		07/12/22	26.8KB	Share
EMD	Upcoming Emyria CEO Webinars		07/12/22	179.42KB	Share
EMD	Emyria accepted into National Institutes of Health Program	PRICE SENSITIVE	28/11/22	636.11KB	Share
EMD	Change of Director's Interest Notice		28/11/22	241.34KB	Share
EMD	Notification regarding unquoted securities - EMD		25/11/22	29.71KB	Share

EMD Application for quotation of securities - EMD
21/11/23		29.03KB	Share
EMD Results of Annual General Meeting
16/11/23		91.89KB	Share
EMD Final Director's Interest Notice - A. Vickery
13/11/23		157.32KB	Share
EMD Board Changes and Executive Restructuring
13/11/23	PRICE SENSITIVE	714.67KB	Share
EMD Section 708A(5)(e) Notice
10/11/23		88.02KB	Share
EMD Application for quotation of securities - EMD
10/11/23		26.82KB	Share
EMD Notification regarding unquoted securities - EMD
10/11/23		30.81KB	Share
EMD Change of Director's Interest Notice - A. Vickery
10/11/23		286.07KB	Share
EMD Results of General Meeting
31/10/23		101.9KB	Share
EMD Emyria Secures Ethics Endorsement for MDMA AP Application
30/10/23	PRICE SENSITIVE	453.79KB	Share
EMD ASA Virtual Investor Summit Presentation October 2023
27/10/23		6.31MB	Share
EMD September 2023 Quarterly Activities Report and Appendix 4C
26/10/23	PRICE SENSITIVE	2.01MB	Share
EMD Change in substantial holding
24/10/23		114.12KB	Share
EMD Health Canada Approval Received for MDMA Import
19/10/23	PRICE SENSITIVE	708.64KB	Share
EMD Letter to Shareholders - Notice of Annual General Meeting
13/10/23		266.63KB	Share
EMD Notice of Annual General Meeting/Proxy Form
13/10/23		519.44KB	Share
EMD Section 708A(5)(e) Notice
10/10/23		87.79KB	Share
EMD Notification of cessation of securities - EMD
10/10/23		23.41KB	Share
EMD Application for quotation of securities - EMD
10/10/23		26.79KB	Share
EMD Change of Director's Interest Notice x 3
10/10/23		364.15KB	Share
EMD Change in substantial holding
10/10/23		137.8KB	Share
EMD Emyria's Clinic Achieves Key MDMA-AT Dosing Milestone
09/10/23	PRICE SENSITIVE	764.02KB	Share
EMD Application for quotation of securities - EMD
05/10/23		26.74KB	Share
EMD Notification regarding unquoted securities - EMD
05/10/23		25.98KB	Share
EMD Completion of Entitlement Offer
05/10/23	PRICE SENSITIVE	784.09KB	Share
EMD Letter to Shareholders - Notice of General Meeting
28/09/23		265.44KB	Share
EMD Notice of General Meeting/Proxy Form
28/09/23		474.82KB	Share
EMD 2023 Annual Report
27/09/23		4.81MB	Share
EMD Appendix 4G and Corporate Governance Statement
27/09/23		489.9KB	Share
EMD Emyria Secures Local MDMA to Start PTSD Trial Dosing
21/09/23	PRICE SENSITIVE	770.68KB	Share
EMD Prospectus & Application Forms Available to Eligible Holders
18/09/23		169.82KB	Share
EMD Notice to Ineligible Shareholders of Entitlement Offer
13/09/23		252.68KB	Share
EMD Section 708A(5)(e) Notice
13/09/23		88.76KB	Share
EMD Emyria Completes Acquisition of the Pax Centre
13/09/23	PRICE SENSITIVE	763.21KB	Share
EMD Application for quotation of securities - EMD
13/09/23		29.24KB	Share
EMD Application for quotation of securities - EMD
13/09/23		26.79KB	Share
EMD Notice to Optionholders - Non-Renounceable Entitlement Offer
06/09/23		231.06KB	Share
EMD Becoming a substantial holder
06/09/23		212.88KB	Share
EMD Strategic Update & Entitlement Offer Presentation
06/09/23	PRICE SENSITIVE	9.15MB	Share
EMD Prospectus
06/09/23	PRICE SENSITIVE	635.86KB	Share
EMD Notification of cessation of securities - EMD
05/09/23		22.87KB	Share
EMD Proposed issue of securities - EMD
04/09/23		57.25KB	Share
EMD Emyria Gets $2M Bids, Sets $3.1M Entitlement Offer
04/09/23	PRICE SENSITIVE	854.7KB	Share
EMD Trading Halt
31/08/23	PRICE SENSITIVE	723.52KB	Share
EMD Appendix 4E Preliminary Financial Report
30/08/23	PRICE SENSITIVE	253.14KB	Share
EMD 2023 Annual General Meeting - Key Dates
30/08/23		220.93KB	Share
EMD Final Director's Interest Notice - M. Callahan
23/08/23		157.11KB	Share
EMD Initial Director's Interest Notice - M. Kaushal
23/08/23		184.96KB	Share
EMD Notification of cessation of securities - EMD
23/08/23		23.18KB	Share
EMD Notification regarding unquoted securities - EMD
23/08/23		29.11KB	Share
EMD Emyria Announces Strategic Board Transition
21/08/23		795.63KB	Share
EMD Change of Director's Interest Notice - A. Vickery
11/08/23		228.3KB	Share
EMD Change of Director's Interest Notice - S. Washer
10/08/23		232.72KB	Share
EMD Change of Director's Interest Notice - M. Winlo
09/08/23		225.45KB	Share
EMD Emyria Launches Ketamine-Assisted Therapy Program
08/08/23	PRICE SENSITIVE	1.22MB	Share
EMD June 2023 Quarterly Activities Report and Appendix 4C
31/07/23	PRICE SENSITIVE	773.99KB	Share
EMD Emyria Recruits First Patient MDMA-Assisted Therapy Trial
10/07/23	PRICE SENSITIVE	925.91KB	Share
EMD Presentation - Pax Acquisition and Company Update
06/07/23	PRICE SENSITIVE	7.92MB	Share
EMD Proposed issue of securities - EMD
03/07/23		25.5KB	Share
EMD Pax Centre Acquisition to Advance Psychedelic Therapies
03/07/23	PRICE SENSITIVE	1.1MB	Share
EMD Trading Halt
29/06/23	PRICE SENSITIVE	374.84KB	Share
EMD Emyria Receives Ethics Approval for MDMA-assisted Therapy
08/06/23	PRICE SENSITIVE	717.18KB	Share
EMD Section 708A(5)(e) Notice
10/05/23		303.92KB	Share
EMD Application for quotation of securities - EMD
10/05/23		26.56KB	Share
EMD Notification regarding unquoted securities - EMD
10/05/23		30.02KB	Share
EMD Proposed issue of securities - EMD
01/05/23		29.17KB	Share
EMD Emyria Completes $2.5m Placement
01/05/23	PRICE SENSITIVE	630.65KB	Share
EMD March 2023 Quarterly Activities Report and Appendix 4C
28/04/23	PRICE SENSITIVE	815.17KB	Share
EMD Trading Halt
27/04/23	PRICE SENSITIVE	700.42KB	Share
EMD Emyria Unveils Highest Potency CBD Capsule for FDA Pathway
24/04/23	PRICE SENSITIVE	631.36KB	Share
EMD Emyria to Develop Psilocybin Therapy Care Model
18/04/23	PRICE SENSITIVE	1.16MB	Share
EMD Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5
04/04/23	PRICE SENSITIVE	1.16MB	Share
EMD Strong Recruitment for EMD-RX5 Phase 3 Trial
23/03/23	PRICE SENSITIVE	1.19MB	Share
EMD Emyria Grows MDMA Asset for Neuro & Mental Health Therapy
20/03/23	PRICE SENSITIVE	638.15KB	Share
EMD Broker Briefing Presentation
16/03/23		6MB	Share
EMD Broker Briefing Biotech & Nutrition Investor Webinar
15/03/23		527.52KB	Share
EMD Emyria partners with PAX Centre for MDMA-assisted therapy
07/03/23	PRICE SENSITIVE	627.19KB	Share
EMD Company Secretary Change
01/03/23		541.02KB	Share
EMD Notice under section 708A(5)(e) of the Corporations Act
27/02/23		304.68KB	Share
EMD Half Yearly Report and Accounts
27/02/23	PRICE SENSITIVE	1.65MB	Share
EMD Investor Presentation
24/02/23		6.55MB	Share
EMD Change of Director's Interest Notice x 5
23/02/23		395.42KB	Share
EMD Notification regarding unquoted securities - EMD
23/02/23		25.44KB	Share
EMD Application for quotation of securities - EMD
23/02/23		26.47KB	Share
EMD Emyria secures clinical-grade MDMA supply for Aust patients
13/02/23	PRICE SENSITIVE	544.06KB	Share
EMD Emyria expands MDMA programs following landmark TGA decision
06/02/23	PRICE SENSITIVE	1.81MB	Share
EMD Appendix 4C - Quarterly
31/01/23	PRICE SENSITIVE	742.38KB	Share
EMD Change in substantial holding SW
31/01/23		102.46KB	Share
EMD First dosing commenced for pivotal EMD-RX5 Phase 3 trial
30/01/23	PRICE SENSITIVE	959.35KB	Share
EMD Results of Meeting
25/01/23		532.4KB	Share
EMD Emyria receives $2.1M R&D tax incentive refund
12/01/23	PRICE SENSITIVE	526.56KB	Share
EMD Biotech Showcase San Francisco Presentation
10/01/23		10.45MB	Share
EMD Notification of cessation of securities - EMD
05/01/23		22.67KB	Share
EMD Letter to Shareholders/Notice of General Meeting/Proxy Form
16/12/22		1.03MB	Share
EMD Notice under section 708A(5)(e) of the Corporations Act
07/12/22		278.45KB	Share
EMD Application for quotation of securities - EMD
07/12/22		26.8KB	Share
EMD Upcoming Emyria CEO Webinars
07/12/22		179.42KB	Share
EMD Emyria accepted into National Institutes of Health Program
28/11/22	PRICE SENSITIVE	636.11KB	Share
EMD Change of Director's Interest Notice
28/11/22		241.34KB	Share
EMD Notification regarding unquoted securities - EMD
25/11/22		29.71KB	Share

REFRESH

First 2 3 4

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 4.9¢		Change 0.003(6.52%)		Mkt cap ! $29.96M

Open	High	Low	Value	Volume
4.7¢	5.1¢	4.6¢	$419.0K	8.556M

Buyers (Bids)

No.	Vol.	Price($)
1	26714	4.9¢

Sellers (Offers)

Price($)	Vol.	No.
5.0¢	180000	3

View Market Depth

No.	Vol.	Price($)
1	26714	0.049
1	4166	0.048
4	362367	0.047
4	236739	0.046
8	371234	0.045

Price($)	Vol.	No.
0.050	180000	3
0.051	100000	2
0.052	202777	3
0.053	36861	2
0.054	24000	1

Last trade - 16.10pm 31/07/2025 (20 minute delay)


Last 4.9¢		Change 0.003 ( 6.52 %)
Open	High	Low	Volume
4.7¢	5.0¢	4.6¢	2343943
Last updated 15.57pm 31/07/2025 ?

EMD (ASX) Chart

EMYRIA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

A new NASDAQ listing for a key player in the global critical minerals space

Top Stories